VANCOUVER, British Columbia, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F)
(the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of
pharmaceutical and wellness products, is pleased to announce the appointment of Dr. Ronald Aung-Din as a Medical, Science and
Development Advisor to the Company.
Dr. Aung-Din, a board-certified neurologist with more than 25 years of practice in general neurology and neuro-psychiatry, joins
Isodiol after pioneering significant scientific advancements in the medical community. During his tenure, Dr. Aung-Din
participated in more than 60 pharmaceutical-sponsored studies that proved to be instrumental in the development of numerous drugs
for utilization and treatment of degenerative and neurological conditions.
In this role, Dr. Aung-Din will aid in the development of a series of new products designed to have a profound impact on the
daily lives of those suffering from symptoms of peripheral neuropathy, cluster headaches, migraines, Parkinson’s disease, multiple
sclerosis, and other debilitating conditions.
"We are excited to welcome Dr. Ronald Aung-Din to Isodiol and are confident that he will be a valuable addition to the team,”
said Marcos Agramont, CEO of Isodiol. “We have been working with neurologists and physicians in Brazil to bring relief to patients
and have already seen tremendous success with our efforts. This is expected to not only continue, but strengthen with the expertise
of Dr. Aung Din."
Dr. Aung-Din has also patented several other drug delivery systems that are currently being utilized today. It is with Dr.
Aung-Din's patented Direct Effects Topical Delivery System that the Company is currently delivering its proprietary cannabidiol
under the brand name IsoDerm. IsoDerm has recently been approved by National Health Surveillance Agency of Brazil (ANVISA) and is
listed on Brazil's special category list allowing physicians to be able to prescribe this product for their
patients. Isodiol has licensed these products and formulations that Dr. Aung-Din has developed and will commence further
development and ultimate distribution on a global basis. Details of this agreement can be read here.
Isodiol has also completed an additional round of financing. The intent of the raise is to fund recent acquisitions and allow
the company to remain flexible in M&A transactions and future international expansion. The Company raised a total of
$9,016,000.00 CAD by issuing 12,183,783 units at $.74 with a full three-year warrant at $.75. All financing units are subject
to a four (4) month hold period.
The round was led by Serruya Private Equity, a family-managed private equity group with a heritage of developing brands and
participating in such global opportunities.
"The Serruya family is pleased to participate in a material way in this recent round of financing by Isodiol," stated Aaron
Nathaniel Serruya. "As we have seen with our sponsorship of Aphria and others in this space, those companies with exceptional
leadership and intellectual property will thrive in this industry and we believe that Isodiol has both of these components."
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International
Isodiol International Inc. is the market leader in pharmaceutical grade
phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive
pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin
care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical
portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
Forward-Looking Information: This news release contains "forward-looking
information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and
future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the
expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will
prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking
statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially
from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will
vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as
required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or
forward-looking information in this news release. Although the Company believes that the expectations reflected in the
forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no
reference to profitability based on sales reported. The statements in this news release are made as of the date of this
release.
The CSE has not reviewed, approved or disapproved the content of this press release.
